Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest PharmaTechQPTFF Earnings per Share (Diluted) is $0.02 as of Jan. 2026. Among 1,160 Biotechnology companies, Quest PharmaTech ranks worse than 86206.81% on this metric.
Quest PharmaTech's EPS (Basic) for the
three
months ended in Jan. 2026 was $0.02.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2026 was $0.02.
During the past 13 years, Quest PharmaTech's highest 3-Year average EPS without NRI Growth Rate was 71.50% per year. The lowest was -128.50% per year. And the median was 0.00% per year.
Quest PharmaTech (OTCPK:QPTFF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Quest PharmaTech Earnings per Share (Diluted) Related Terms
Quest PharmaTech Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Quest PharmaTech's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest PharmaTech Earnings per Share (Diluted) Chart
QPTFF vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Quest PharmaTech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest PharmaTech PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quest PharmaTech's PE Ratio distribution charts can be found below:
* The bar in red indicates where Quest PharmaTech's PE Ratio falls into.
Quest PharmaTech Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Quest PharmaTech's Earnings Per Share (Diluted) for the fiscal year that ended in Jan. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.02 mean?
Quest PharmaTech (QPTFF) has a Earnings per Share (Diluted) of $0.02 as of Jan. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Quest PharmaTech and its competitors. According to the industry distribution chart, Quest PharmaTech ranks #999999 out of 1160 companies in the Biotechnology industry.
Is Quest PharmaTech's Earnings per Share (Diluted) too high?
Quest PharmaTech's current Earnings per Share (Diluted) is $0.02. The Biotechnology industry median Earnings per Share (Diluted) is 16.05. Quest PharmaTech's value of $0.02 is 99.9% below this industry median. Based on the distribution chart, Quest PharmaTech ranks #999999 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Quest PharmaTech's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quest PharmaTech ranks #999999 out of 1160 companies for Earnings per Share (Diluted). This places Quest PharmaTech in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.05. Quest PharmaTech's value of $0.02 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest PharmaTech's current Earnings per Share (Diluted) of $0.02 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Quest PharmaTech and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest PharmaTech's current Earnings per Share (Diluted) is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current Earnings per Share (Diluted) of $0.02. The current Earnings per Share (Diluted) is $0.02 and 99.9% below the Biotechnology industry median of 16.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current Earnings per Share (Diluted) is $0.02 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QPTFF has been successfully added to your 
